Communiqués Cocrystal Pharma, Inc.

Actions

COCP

US19188J4094

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 05/07/2024			Varia. 5j.	Varia. 1 janv.
2,38 ^USD	+3,48 %		+2,15 %	+38,20 %

20/06	Cocrystal Pharma fait progresser le Cc-42344 dans l'étude de phase 2A sur la grippe A et prévoit des résultats de première ligne d'ici fin 2024	CI
13/05	Cocrystal Pharma, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows	20/06	AQ
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	13/05	AQ
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza	01/05	AQ
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	28/03	AQ
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A	19/03	AQ
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates	04/01	AQ
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A	06/12	AQ
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	29/11	AQ
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023	27/11	AQ
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	13/11	AQ
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	09/11	AQ
Cocrystal Pharma : Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 - Form 8-K	31/10/23	PU
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344	31/10/23	AQ
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus	28/09/23	AQ
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference	05/09/23	AQ
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	14/08/23	AQ
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead	08/08/23	AQ
Cocrystal Pharma : Investor Presentation	24/06/23	PU
Cocrystal Pharma : Market Offering Agreement - Form 8-K	15/06/23	PU
Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988	31/05/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cocrystal Pharma, Inc.

Actions

COCP

US19188J4094

Communiqués

Filtres